Fjarde Ap Fonden Incyte Corp Transaction History

Fjarde Ap Fonden

$10.8 Billion
Q2 2025

A detailed history of Fjarde Ap Fonden transactions in Incyte Corp stock. As of the latest transaction made, Fjarde Ap Fonden holds 121,364 shares of INCY stock, worth $9.49 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

121,364

Previous 95,564 27.0%

Holding current value

$9.49 Million

Previous $5.79 Million 42.84%

% of portfolio

0.08%

Previous 0.07%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 01, 2025	BUY	$55.17 - $71.22 $1.42 Million - $1.84 Million	25,800 Added 27.0%	121,364 $8.27 Million
Q1 2025 May 13, 2025	BUY	$60.0 - $75.26 $1.28 Million - $1.6 Million	21,300 Added 28.68%	95,564 $5.79 Million
Q4 2024 Feb 04, 2025	SELL	$65.08 - $83.38 $1.6 Million - $2.05 Million	-24,600 Reduced 24.88%	74,264 $5.13 Million
Q3 2024 Nov 08, 2024	SELL	$57.33 - $68.61 $945,945 - $1.13 Million	-16,500 Reduced 14.3%	98,864 $6.54 Million
Q1 2024 Apr 25, 2024	BUY	$56.55 - $66.59 $1.29 Million - $1.52 Million	22,800 Added 24.63%	115,364 $6.57 Million
Q4 2023 Feb 14, 2024	SELL	$52.16 - $64.19 $751,104 - $924,336	-14,400 Reduced 13.46%	92,564 $5.81 Million
Q3 2023 Oct 23, 2023	BUY	$57.77 - $65.93 $340,843 - $388,987	5,900 Added 5.84%	106,964 $6.18 Million
Q2 2023 Aug 02, 2023	BUY	$60.95 - $75.51 $1.24 Million - $1.54 Million	20,400 Added 25.29%	101,064 $6.29 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $832,225 - $1.02 Million	11,850 Added 17.22%	80,664 $5.83 Million
Q4 2022 Feb 14, 2023	SELL	$67.18 - $84.11 $866,957 - $1.09 Million	-12,905 Reduced 15.79%	68,814 $5.53 Million
Q2 2022 Aug 11, 2022	BUY	$66.18 - $83.18 $2.63 Million - $3.3 Million	39,700 Added 94.48%	81,719 $6.21 Million
Q1 2022 May 13, 2022	SELL	$66.02 - $79.71 $970,493 - $1.17 Million	-14,700 Reduced 25.92%	42,019 $3.34 Million
Q4 2021 Feb 15, 2022	SELL	$63.34 - $74.11 $83,988 - $98,269	-1,326 Reduced 2.28%	56,719 $4.16 Million
Q3 2021 Nov 15, 2021	BUY	$68.67 - $84.02 $185,409 - $226,854	2,700 Added 4.88%	58,045 $3.99 Million
Q2 2021 Aug 12, 2021	SELL	$79.87 - $87.53 $391,363 - $428,897	-4,900 Reduced 8.13%	55,345 $4.66 Million
Q1 2021 May 17, 2021	BUY	$76.02 - $100.5 $744,996 - $984,900	9,800 Added 19.43%	60,245 $4.9 Million
Q4 2020 Feb 12, 2021	SELL	$80.74 - $97.7 $379,478 - $459,190	-4,700 Reduced 8.52%	50,445 $4.39 Million
Q3 2020 Nov 13, 2020	BUY	$85.07 - $109.69 $399,828 - $515,543	4,700 Added 9.32%	55,145 $4.95 Million
Q2 2020 Aug 13, 2020	BUY	$74.18 - $108.93 $57,712 - $84,747	778 Added 1.57%	50,445 $5.25 Million
Q1 2020 May 11, 2020	BUY	$63.18 - $85.97 $37,908 - $51,582	600 Added 1.22%	49,667 $3.64 Million
Q4 2019 Feb 10, 2020	BUY	$73.04 - $95.72 $387,112 - $507,316	5,300 Added 12.11%	49,067 $4.29 Million
Q3 2019 Oct 31, 2019	BUY	$72.82 - $86.52 $131,076 - $155,736	1,800 Added 4.29%	43,767 $3.25 Million
Q2 2019 Jul 17, 2019	SELL	$73.52 - $88.7 $551,400 - $665,250	-7,500 Reduced 15.16%	41,967 $3.57 Million
Q1 2019 Apr 29, 2019	BUY	$63.56 - $88.17 $589,709 - $818,041	9,278 Added 23.09%	49,467 $4.26 Million
Q4 2018 Jan 31, 2019	SELL	$58.5 - $69.94 $462,150 - $552,526	-7,900 Reduced 16.43%	40,189 $2.56 Million
Q3 2018 Nov 09, 2018	SELL	$61.75 - $74.23 $87,499 - $105,183	-1,417 Reduced 2.86%	48,089 $3.32 Million
Q2 2018 Jul 12, 2018	BUY	$60.85 - $83.98 $19,715 - $27,209	324 Added 0.66%	49,506 $3.32 Million
Q1 2018 May 07, 2018	BUY	$83.06 - $100.98 $156,318 - $190,044	1,882 Added 3.98%	49,182 $4.1 Million
Q4 2017 Feb 12, 2018	BUY	$93.56 - $116.6 $588,211 - $733,064	6,287 Added 15.33%	47,300 $4.48 Million
Q3 2017 Nov 07, 2017	BUY	$109.15 - $138.27 $153,792 - $194,822	1,409 Added 3.56%	41,013 $4.79 Million
Q2 2017 Aug 08, 2017	BUY	N/A	39,604	39,604 $4.99 Million

Others Institutions Holding INCY

# of Institutions

706

Shares Held

194M

Call Options Held

564K

Put Options Held

317K

View Full List

About INCYTE CORP

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $17.4B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

More about INCY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

News

Stay updated on Fjarde Ap Fonden with notifications on news.

Account